Medical Devices

On January 19, the NMPA announced the new clinical trial exemption list for medical devices and in-vitro diagnostics reagents.

A total number of 10579 applications and 9849 approvals for medical device registrations in China were reported in 2020 along with a detailed breakdown.

Ultrasonic coupling agents are reminded to comply with mandatory standards and any necessary filing changes must be completed by the end of February 2021.

The new draft clarifies the registration requirements and categorization method of different drug-device combination products in China.

3 GB standards announced; 14 technical guidelines and 2 draft guidelines were issued; 6 medical devices pending for fast-track approval

Due to the 2020 performance of the fast-track approval process for medical device registration in China, the CDME plans to implement a smart review process.

The NMPA issued guidelines to address the standard procedure of submitting risk evaluation reports after the occurrence of adverse events.

The CMDE shared a timeline of events for establishing regulatory control on AI medical devices and shared the latest status of their upcoming plans.

The State Administration for Market Regulation addressed the innovative development plan actions for drugs and medical devices in the Greater Bay Area.

China’s NMPA issues technical guidelines (trial) for utilizing real-world data (RWD) in the medical device clinical evaluation process.

Following the launch of the China’s national UDI system, the Hainan MPA has announced a pilot plan for the UDI system in Hainan with a larger product scope.

The draft guidelines cover real-time fluorescent PCR analyzers, disposable non-absorbent closure clamps, nanomaterials, and intravascular catheters